Actinium Pharmaceuticals Inc. is receiving an up-front $35 million with a possible $417 million in regulatory and commercial milestones in its new license and supply agreement with Immedica Pharma AB, of Stockholm. Immedica is getting the exclusive European, Middle Eastern and North African rights to Iomab-B, an antibody radiation conjugate comprising apamistamab, a CD45-targeting antibody, and the radioisotope iodine-131. Actinium is eligible for royalties in the mid-20% range on net sales. Read More
Takeda Pharmaceutical Co. Ltd. has stress-tested Engitix Ltd.’s extracellular matrix (ECM) drug discovery platform and is coming back for more, expanding the existing collaboration from liver fibrosis to inflammatory bowel disease (IBD). Read More
Telix Pharmaceuticals Ltd. has in-licensed Eli Lilly and Co.’s olaratumab antibody, agreeing to pay $5 million up front for exclusive worldwide rights to develop and commercialize radiolabeled forms of the antibody for the diagnosis and treatment of human cancers. Read More
Cellpoint B.V. has picked up U.S and European rights to a chimeric antigen receptor T-cell (CAR T) therapy from Shenzhen Pregene Biopharma Co. Ltd. Cellpoint will develop and commercialize the candidate, PRG-1801, for the treatment of hematological indications. Read More
The U.K. plan to fix the market failure in antibiotics has taken a significant step forward with the publication of guidance estimating the value of two drugs to the National Health Service. Read More
Making it a done deal, the European Council adopted proposals April 12 to ensure the continued long-term supply of medicines from Great Britain to Northern Ireland and to address supply concerns in Cyprus, Ireland and Malta, which historically have been dependent on drugs from the U.K. Read More
The twos have it as the U.S. FDA’s Office of Prescription Drug Promotion, in its second untitled letter of the year, took Bausch Health Cos. Inc. to task over two promotions of its plaque psoriasis lotion, Duobrii (halobetasol propionate and tazarotene). Read More
New hires and promotions in the biopharma industry, including: Alltrna, Alx Oncology, Eton, Flagship Pioneering, Freya, Illumina, Innoskel, Invectys, MD Anderson, Nautilus, Neuron23, Oak Hill, Radionetics, Renovion, Sitryx, Vedere, Vera. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aquestive, Caladrius, Chinook, Cocrystal, Dare, Gannex, Immune-Onc, Inozyme, IO Biotech, Nabriva. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Agenus, Aprinoia, Curis, Glenmark, Merck & Co., Priothera, Recursion, Scpharmaceuticals, Spectrum. Read More
